Hemostemix Issues Letter to Shareholders Urging Them to Vote Their WHITE Proxy
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 08/29/16 --
Hemostemix Inc. ("Hemostemix") (TSX VENTURE: HEM)(OTCQX: HMTXF) today released a letter to shareholders highlighting the benefits of voting in favour of the current experienced, trusted board and encourages shareholders to vote their WHITE proxy to stay the course. The letter confirms that the dissidents'' proposed changes to the board are not in the best interests of all shareholders, and reminds them they may revoke a blue proxy by completing and delivering their white form of proxy. Hemostemix has engaged Norton Rose Fulbright Canada LLP as their legal advisor and Kingsdale Shareholder Services as their strategic advisor and proxy solicitation agent.
Dear Fellow Hemostemix Shareholder:
We are writing to seek your support for YOUR Company, Hemostemix Inc. A group of self-interested dissident shareholders (the Dissidents) with no industry experience are attempting to ambush shareholders at the company''s annual meeting, seize control of Hemostemix'' intellectual property and take over your Board.
In order to grab control of Hemostemix, the Dissidents have made unfounded accusations and provided misleading information about your company and management.
Here are the facts:
Now is not the time to risk the future of Hemostemix and our valuable intellectual property to unproven, inexperienced Dissidents with a self-interested agenda premised on dubious medical practices. Only our STRENGHTENED Board and EXPERIENCED Management Team have a CLEAR STRATEGY that WILL lead to the creation of SHAREHOLDER VALUE.
Our vision is to build a leading world-class biotech company. The Dissidents'' agenda is dangerous - they want to scale back clinical trials and move our business to jurisdictions with poor regulatory oversight. We cannot allow these unknown and inexperienced opportunists to attack your company and destroy its future.
VOTE THE WHITE PROXY TO SUPPORT YOUR COMPANY''S TRUSTED BOARD AND ENSURE THAT THE PROGRESS WE HAVE ACHIEVED IN BRINGING OUR LANDMARK TECHNOLOGY TO MARKET IS NOT LOST!
EXPERIENCED BOARD WITH A PROVEN PLAN TO CREATE VALUE
Our strengthened Board includes extensive biotechnology, pharma, capital markets and legal expertise. Our Life Science Board Members each have unprecedented relevant experience in the healthcare sector; have been involved in the treatment of over 1,000 patients with cell therapies and have a proven track record of success.
Our performance has consistently kept pace with our peers while building a strong foundation for future growth. We have now reached the tipping point of our development process to create even more value for all shareholders. To unlock that value, your management team is leading a number of successful clinical trials. Led by our CEO, Dr. Elmar Burchardt, and members of our Board, we have already achieved significant milestones:
We are on the path to success and in the process of securing the additional financing to advance these trials and monetize our technology. To date, management and key shareholders have invested over $1.2MM of their own capital in non-interest bearing loans to ensure success.
The KEY to realizing this success and to unlock the VALUE is to stay the course.
THE DISSIDENTS'' AGENDA WILL PUT YOUR INVESTMENT AT RISK
The Dissidents want to hijack your company and use its intellectual property for their purposes. They will derail Hemostemix off our path to success and focus instead on the grey market business of medical tourism in unregulated jurisdictions. It is short-sighted, alarming and destructive.
ACCORDING TO THE DISSIDENTS'' PLAN, ALL HEMOSTEMIX ASSETS WILL BE USED AS COLLATERAL TO SECURE THEIR LOAN AND THEY WILL DECIDE IF HEMOSTEMIX GOES INTO DEFAULT AFTER AN INTIAL PAYMENT OF C$ 1 MILLION. IN ESSENCE, THE DISSIDENTS COULD SEIZE ALL HEMOSTEMIX ASSETS FOR C$ 1 MILLION.
Their agenda is to move our current program and clinical trials to Taiwan for premature commercialization. To give up the North American and European markets is foolish. To send your company to Taiwan is negligent.
The Dissidents have NO experience in developing drugs or medical devices - they do not have the knowledge, understanding or the skills needed to take this technology to the next level. What they do have is a track record of orchestrating hostile takeovers. Their involvement will undermine our strategic discussions with pharma and biotech partners and its future.
Shareholders will not benefit by abandoning our successful work or by placing our technology into the hands of a self-interested few without any experience or any track record and no concept of how to move it forward will not result in value to shareholders.
The Dissidents cannot be trusted, look at their past:
With NO plan, NO biotechnology experience and NO control premium offered to Hemostemix shareholders during this critical stage in the company''s development, the Dissidents'' proposed changes to the Board are NOT in the best interests of Hemostemix and its shareholders.
Vote your WHITE proxy FOR your BOARD
Regardless of how many shares you own or whether you plan to attend the upcoming meeting on September 8, 2016 or not, it is imperative that you vote your WHITE proxy.
You may vote your WHITE proxy by internet or telephone, or by signing, dating, and returning the enclosed WHITE proxy by fax to Kingsdale Shareholder Services at 1-866-545-5580 or 416-867-2271. Only your later-dated proxy will count.
Shareholders are urged to vote their WHITE proxy FOR Hemostemix'' current Board of Directors prior to the proxy cut-off at 2:00 p.m. (MDT) on September 6, 2016.
You may revoke a blue proxy already given by completing and delivering your WHITE form of proxy. The later dated WHITE form of proxy revokes any and all prior proxies given by you in connection with the Meeting.
If you have any questions, please contact Kingsdale Shareholder Services at 1-888-518-6832 toll-free in North America, or 416-867-2272 outside North America or by email at .
On behalf of the entire Board and management, we would like to thank you for your continued support of Hemostemix, as we move forward with the execution of our strategy to drive Hemostemix in the right direction.
Yours truly,
(signed) "Angus Jenkins"
Angus Jenkins, Chairman of the Board of Directors
ABOUT HEMOSTEMIX INC.
Hemostemix is a public clinical-stage biotechnology company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. It is the first clinical-stage biotech company to test a stem-cell therapy in an international, multicenter, Phase 2 clinical trial for patients with critical limb ischemia (CLI), a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. The Phase 2 trial targets a participant''s diseased tissue with proprietary cells grown from his or her blood that are capable of supporting the formation of new blood vessels. The company recently received FDA clearance to commence clinical trials in the United States.
Hemostemix Inc. is traded on the TSX Venture Exchange under the trading symbol HEM and on the OTCQX® Best Market under the trading symbol HMTXF. For more information, visit hemostemix.com or email .
Neither the TSX Venture Exchange Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD-LOOKING STATEMENTS
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," and similar expressions, or that events or conditions "will," "would," "may," "could," or "should" occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.
Contacts:Hemostemix Inc.David BermanChief Financial Officer
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.08.2016 - 06:30 Uhr
Sprache: Deutsch
News-ID 1454915
Anzahl Zeichen: 2531
contact information:
Contact person:
Town:
TORONTO, ONTARIO
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 167 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Hemostemix Issues Letter to Shareholders Urging Them to Vote Their WHITE Proxy
"
steht unter der journalistisch-redaktionellen Verantwortung von
Hemostemix Inc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
